Blood-based gene expression profiling in castrate-resistant prostate cancer

Mitchell E. Gross

Abstract
Castrate-resistant prostate cancer (CRPC), the most life-threatening form of prostate cancer, has recently been the focus of many successful new treatments. Contemporary trials highlight the heterogeneous prognosis of CRPC as overall survival times vary greatly across different patient sub-groups. As presented in BMC Medicine, Wang et al. identify a blood-based prognostic signature in CRPC. Their approach is notable for discovery and validation of a four-gene model based on a whole-blood expression signature sampled from three distinct clinical cohorts. Further, the marker selection process incorporates an understanding of biological pathways expressed in myeloid or lymphoid cells which may provide some insight into host-tumor interactions as reflected in the peripheral blood. While the study includes a multivariate analysis accounting for many important clinical variables, larger datasets with more complete clinical information and sufficient follow-up are needed to confirm the independent significance of the four-gene expression model in a way which may better inform the care of CRPC patients.

Please see related article: http://www.biomedcentral.com/1741-7015/13/201.

Keywords: Castrate-resistant prostate cancer, Gene expression profiling, Prognostic biomarker

Introduction
Prostate cancer is a heterogeneous disease. At diagnosis, clinical and pathologic features, such as prostate specific antigen level, pathologic Gleason grade, and tumor stage, are used to inform clinical decision making [1]. For some patients, prognostic factors are interpreted as favorable (and the disease is projected to proceed slowly) that no active therapy is pursued (“watchful waiting” or “active surveillance”). Other patients are diagnosed with a highly aggressive form of prostate cancer which is either metastatic at diagnosis or recurs after local therapy (typically surgery or radiation). Androgen-deprivation therapy is the mainstay of therapy for metastatic/recurrent prostate cancer. However, cancer can progress despite medical or surgical castration to castrate-resistant prostate cancer (CRPC).

Heterogeneity is also noted among patients with advanced and recurrent forms of prostate cancer. While CRPC is the most dangerous, and often fatal, form of prostate cancer, median survival times reported for patients treated with highly-active androgen targeting agents in chemotherapy-naïve CRPC are well over 24 months in most contemporary trials [2, 3]. In contrast, active treatment with a bone-targeted radiopharmaceutical (Radium-223) in chemotherapy-naïve patients in a recent trial reported a median survival of only 14 months in the active treatment arm [4]. While the later trial focused on subjects who were deemed not candidates for cytotoxic chemotherapy based on physician discretion or patient preference, the inclusion criteria between these trials were generally overlapping. Thus, there is an opportunity to explore readily-obtained, objective biomarkers to more accurately determine prognosis in CRPC.

Wang et al. [5] sought to define a prognostic model in CRPC based on analysis of a whole-blood RNA expression signature. Starting with expression data generated in a publicly available data set [6], the authors identified co-expression modules for gene sets which discriminate based on prognosis. When grouped and compared with other annotated gene expression signatures, the “up modules” were enriched for genes associated with erythroid and myeloid cells, while “down modules” were
enriched for genes associated with B and T lymphocytes. Genes representing the greatest differences in expression levels between good and poor risk groups were used to develop a prognostic model using a Bayesian learning algorithm. A four-gene model incorporating MCM2, PROS1, CD22, and TMEM66 performed best in cross-validation tests and was selected for further assessment. The model was tested in two separate cohorts of patients totaling 90 patients and was shown to add statistically significant prognostic information to standard clinical prognostic variables.

Whole blood expression signatures have been examined in relation to prognosis for prostate and other forms of cancer [6–9]. Relatively unique in the Wang et al. [5] study is the overlay of functional information, including cell-type-specific expression patterns and pathway information, with gene expression. Thus, it is interesting to note that up-regulation of myeloid-associated genes was associated with a worse prognosis consistent with the finding that increases in tumor-associated macrophages confer a worse prognosis [10, 11]. The increased expression of myeloid relative to lymphoid markers in poor risk patients is also consistent with other studies focusing on the neutrophil to lymphocyte ratio, obtained with a standard peripheral blood count, as an independent prognostic factor in CRPC [12–15]. Immune activation in relation to prostate cancer is an area of great interest. Many studies have sought to identify associations and mechanisms between specific immune cells with the development and progression of prostate cancer [16]. This focus is further heightened by the use of an immuno-therapy (sipuleucel-T) for patients with CRPC [17]. It is interesting to consider how approaches like whole-blood expression signatures can help characterize the nature of immune-activation directed against cancer in hopes of more specifically stimulating tumor-immunity with therapeutic intent.

Conclusion
The therapeutic landscape of CRPC has changed rapidly in the last few years as entirely new classes of therapies (high-potency androgen targeting agents, bone-targeted radiopharmaceuticals, immunotherapy) have been added to conventional hormonal and chemotherapy agents approved for CRPC, often with overlapping indications. While improved prognostic markers are significant, there is an even greater need to find biomarkers to select patients for specific therapies. The study by Wang et al. [5] suggests that a biologically-informed approach to the analysis of blood-based expression signatures may be one approach towards this goal.

Author’s information
Dr. Gross is an Associate Professor of Medicine and Urology at the Keck School of Medicine, University of Southern California and serves as the Research Director of the USC Westside Cancer Center and the Center for Applied Molecular Medicine.

Received: 27 August 2015 Accepted: 27 August 2015
Published online: 14 September 2015

References
1. Parker C, Gillessen S, Heinzenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v69–77.
2. Ryan C, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.
3. Bode TM, Armstrong AJ, Rathkopf DE, Loriot Y, Stemberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
4. Parker C, Nilsson S, Heinrich D, Helle S, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
5. Wang L, Gong Y, Chippada-Venkata U, Heck MW, Retz M, Nawroth R, et al. A robust blood gene expression-based prognostic model for castrate-resistant prostate cancer. BMC Med. 2015;13:201.
6. Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 2012;13:1114–24.
7. Ross RW, Galisky MD, Scher HI, Magdison J, Wassmann K, Lee GS, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012;13:1105–13.
8. Tudorone O, Vrinc T, Balaceo C, Pop L, Dragla F, Eniu A, et al. Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One. 2014;9:e102764.
9. Carloni L, Hosseinian S, Monnier-Benof S, Imajuku N, Dotta G, Ruegg C, et al. Discovery of a 29-gene panel in peripheral blood mononuclear cells for the detection of colorectal cancer and adenomas using high throughput real-time PCR. PLoS One. 2015;10:e0123904.
10. Gallapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, et al. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res. 2013;3:523–9.
11. Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011;107:1918–22.
12. Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Feraleschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26:750–5.
13. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, et al. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014;12:37–44.
14. Templeton AJ, Pezaro C, Ominl A, McNamara MG, Liebowitz-Amrit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120:3346–52.
15. van Soest RI, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015;26:743–9.
16. Strasser A, Karin M. Immune infiltration and prostate cancer. Front Oncol. 2015;5:128.
17. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Petron DJ, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.